BRISTOL MYERS SQUIBB

๐Ÿ‡ซ๐Ÿ‡ทFrance
Ownership
-
Established
1989-01-01
Employees
30K
Market Cap
$97.5B
Website
https://www.bms.com/

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-03-12
Last Posted Date
2013-11-25
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
2711
Registration Number
NCT00633893
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Mercury Street Medical Group, Pllc, Butte, Montana, United States

๐Ÿ‡บ๐Ÿ‡ธ

Piedmont Healthcare/Research, Statesville, North Carolina, United States

๐Ÿ‡บ๐Ÿ‡ธ

William Beaumont Hospital, Royal Oak, Michigan, United States

and more 84 locations

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-02-26
Last Posted Date
2014-06-09
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
99
Registration Number
NCT00623766
Locations
๐Ÿ‡บ๐Ÿ‡ธ

The Angeles Clinic & Research Institute, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Loyola University Medical Center, Maywood, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Seattle Cancer Care Alliance, Seattle, Washington, United States

and more 11 locations

Phase II, 2nd Line Melanoma - RAND Monotherapy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-02-12
Last Posted Date
2015-10-12
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
158
Registration Number
NCT00612664
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Blumenthal Cancer Center, Carolinas Medical Center, Charlotte, North Carolina, United States

๐Ÿ‡บ๐Ÿ‡ธ

Harry & Jeanette Weinberg Cancer Inst At Franklin Square, Baltimore, Maryland, United States

๐Ÿ‡บ๐Ÿ‡ธ

Yale University School Of Medicine, New Haven, Connecticut, United States

and more 8 locations

Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-01-31
Last Posted Date
2011-01-25
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
8
Registration Number
NCT00605618
Locations
๐Ÿ‡ฆ๐Ÿ‡บ

Local Institution, Kogarah, New South Wales, Australia

A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection

First Posted Date
2008-01-31
Last Posted Date
2010-11-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
4
Registration Number
NCT00605384
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Cedars Sinai Medical Center, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Kaiser Permanente Medical Center, San Francisco, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Rush University Medical Center, Chicago, Illinois, United States

and more 1 locations

PoC in Rheumatoid Arthritis With Methotrexate

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-01-31
Last Posted Date
2015-10-12
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
121
Registration Number
NCT00605735
Locations
๐Ÿ‡บ๐Ÿ‡ธ

G. Timothy Kelly, Md, Las Vegas, Nevada, United States

๐Ÿ‡จ๐Ÿ‡ณ

Local Institution, Taoyuan, Taiwan

๐Ÿ‡บ๐Ÿ‡ธ

The Arthritis Group, Philadelphia, Pennsylvania, United States

and more 6 locations

Phase I/II Combination With Irinotecan- Erbitux

First Posted Date
2008-01-16
Last Posted Date
2015-11-04
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
38
Registration Number
NCT00594984
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Usc/Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Washington University, Saint Louis, Missouri, United States

and more 2 locations

Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-01-15
Last Posted Date
2013-05-22
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
15
Registration Number
NCT00593944
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Oncology Consultants, PA, Houston, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Roswell Park Cancer Institute, Buffalo, New York, United States

Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2007-12-21
Last Posted Date
2008-07-31
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
17
Registration Number
NCT00578916
Locations
๐Ÿ‡จ๐Ÿ‡ญ

Local Institution, Allschwil, Switzerland

Belatacept Pharmacokinetic Trial in Renal Transplantation

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-12-21
Last Posted Date
2014-01-17
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
14
Registration Number
NCT00578448
Locations
๐Ÿ‡ฒ๐Ÿ‡ฝ

Local Institution, Aguascalientes, Mexico

๐Ÿ‡บ๐Ÿ‡ธ

Western New England Renal & Transplant, Springfield, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Henry Ford Hospital, Detriot, Michigan, United States

ยฉ Copyright 2024. All Rights Reserved by MedPath